Starling Oncology, Inc.
STLNW- Exchange
- Nasdaq
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $163.5K in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Starling Oncology, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 15 | 18 | +3 |
| Shares | 4.12M | 4.25M | +136.2K (+3.3%) |
| Value | $827.5K | $108.0K | −$719.5K (−87.0%) |
New holders (3)
Institutions that held Starling Oncology, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 8,789 | $229 | 0.00% |
| HRT Financial LP | 11,098 | $0 | 0.00% |
| Virtu Financial LLC | 12,749 | $0 | 0.00% |
Sold out (0)
Institutions that held Starling Oncology, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
None.